Highest-materiality recent filing
Company furnished a supplemental Q&A document responding to shareholder questions about Q1 2026 earnings.
Clover Health posts Q1 GAAP net income of $27M; revenue up 62% YoY
GAAP net income $27.3M vs $(1.3)M in Q1 2025; first positive GAAP net income quarter.
Clover Health CFO Peter Kuipers steps down; Clay Thornton named interim CFO
Peter Kuipers resigns as CFO effective March 30, 2026; will advise through April 24, 2026.
Clover Health publishes supplemental shareholder Q&A; no new financial data disclosed
Filed 8-K/A on March 6, 2026 furnishing a supplemental Q&A document related to Q4 2025 earnings.
Clover Health publishes supplemental Q&A re Q4 2025 earnings
Filed under Item 7.01; responses to frequently asked questions from shareholders.
Full year 2025 total revenues of $1.9 billion, up 40% year-over-year; GAAP net loss of $86 million.
Medicare Advantage membership grew 53% YoY to ~153,000 as of Jan 1, 2026, driven by disciplined core-market growth.
Clover Health discloses Counterpart Assistant performance update for external payors
Counterpart Health subsidiary released performance outcomes and clinician adoption data for Counterpart Assistant technology.
Clover Health publishes supplemental Q&A on Q3 2025 earnings; no new financial figures disclosed
Filed under Regulation FD on Nov 12, 2025; document contains written responses to shareholder questions.
Clover Health Q3 revenue up 50% YoY to $497M, but cuts FY25 adjusted EBITDA guidance to $15M-$30M
Q3 GAAP net loss $24.4M; revenue $496.7M vs $331M YoY; membership 109,226 (+35% YoY).
Chelsea Clinton steps down from Clover Health Board effective Oct 31, 2025
Clinton notified the Company on October 31, 2025; departure is immediate and not due to any disagreement.
CMS awarded Clover's PPO plans 3.5 Stars and HMO plan 4.0 Stars for 2026 ratings, affecting payment year 2027.
Executive chairman's Q&A highlights Clover's PPO success and AI edge
Vivek Garipalli answers two shareholder questions on PPO model viability and AI in healthcare.
Clover Health Q2 revenue $478M (+34% YoY), membership up 32%, GAAP net loss $11M
Q2 2025 total revenues $477.6M, up 34% YoY; insurance revenue $469.8M (+34.3%).
Clover Health stockholders elect directors, approve pay, ratify auditor at 2025 annual meeting
Dr. Anna U. Loengard and William G. Robinson, Jr. elected as Class I directors for term expiring 2028.
Clover Health publishes shareholder Q&A ahead of Q1 2025 earnings; no financial data disclosed
Shareholder Q&A published on May 14, 2025 covering 10 frequently asked questions.
Clover Health Q1 beat: revenue $462M (+33%), Adj EBITDA $26M (+279%); raises FY guidance
Q1 total revenue $462M, up 33% YoY; GAAP net loss improved to $1M from $19M loss a year ago.
Clover Health board member Lee Shapiro to not stand for re-election; Tran to chair committees
Lee Shapiro will not stand for re-election due to American Heart Association chairmanship; departure effective June 10, 2025.
Clover Health FY24 adjusted EBITDA $70M, net loss improves $164M; 2025 revenue guidance $1.8-1.875B
Full year 2024 GAAP net loss from continuing ops narrowed to $46M from $210M in 2023 (improvement of $164M).
Clover Health reports 27% MA membership growth, surpasses 100,000 members after AEP
Medicare Advantage membership grew 27% YoY to over 100,000 as of January 1, 2025.
Clover Health Q3 net loss narrows to $8.8M; raises FY 2024 Adj. EBITDA guidance to $55-65M
GAAP net loss from continuing ops improved to $8.8M from $33.6M YoY; Adjusted EBITDA rose to $19.3M from $2.7M.
Clover Health pays $250,000 to settle shareholder lawsuit fee claim
Plaintiff challenged board nomination bylaw as preclusive; company amended bylaw to moot action.
Clover Health's PPO Medicare Advantage Plans Earn 4 Star Rating from CMS for 2025
CMS raised Clover Health PPO Medicare Advantage plans to 4 Stars for 2025, affecting payment year 2026.
SEC concludes Clover Health investigation, will not recommend enforcement action
SEC staff notified Clover Health on Sept 26, 2024 that the investigation begun in Feb 2021 is closed.
Clover Health appoints former Molina Healthcare CFO Thomas L. Tran to Board and Audit Committee
Thomas L. Tran appointed Class II director and Audit Committee member; Board expanded from 8 to 9.
Clover Health Q2 2024: first GAAP net income of $7.2M, raises FY2024 guidance
Q2 GAAP net income from continuing operations $7.2M vs. loss of $28.9M in Q2 2023; first positive quarter.
Court approves settlement of Clover Health derivative suits, dismisses cases with prejudice
Court approved settlement of four consolidated shareholder derivative actions against Clover and its directors.
Clover Health regains Nasdaq minimum bid price compliance after 10-day streak above $1.00
Received formal Nasdaq notice on June 26, 2024 that compliance with Listing Rule 5450(a)(1) is regained.
Clover Health amends bylaws to modify 'Acting in Concert' definition
Board unanimously adopted Second Amended and Restated Bylaws on June 19, 2024, effective immediately.
CMS upgrades Clover Health PPO Medicare Advantage Star rating to 3.5 for 2025
CMS recalculated Star rating from 3.0 to 3.5 Stars for 2025 payment year.
Elected Chelsea Clinton, Carladenise Armbrister Edwards, and Vivek Garipalli as Class III directors with over 937M votes each.
Clover Health launches Counterpart Assistant for external payors, expanding SaaS platform
Clover Assistant rebranded as Counterpart Assistant; now generally available to external Medicare Advantage payors and providers.
Clover Health Q1 2024: first Adj. EBITDA profit $6.8M; guides to full-year profitability
Insurance revenue $341.7M (+7.8% YoY); total revenue $346.9M.
Clover Health names Peter Kuipers as CFO; targets adjusted EBITDA profitability in 2024
Peter Kuipers appointed CFO effective after Q1 2024 10-Q filing; succeeds interim CFO Terrence Ronan.
Received Nasdaq notice on April 2, 2024 for CLOV closing below $1.00 for 30 consecutive business days.
Clover Health resolves derivative suits; $2.5M counsel fees, governance changes
Settlement requires no monetary payment to shareholders; $2.5M in fees to plaintiffs' counsel subject to court approval.
Clover Health FY 2023 net loss improves to $213.4M; Insurance MCR drops to 81.2%
Full-year 2023 net loss of $213.4M vs $339.6M in 2022; Insurance MCR improved to 81.2% from 91.8%.
Mr. Shapiro will fulfill the remainder of his term as member of the Board of Directors and the effective date of his departure will be the Company’s Annual Meeting of Shareholders, June 10, 2025.
On August 20, 2024, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Thomas L. Tran, to serve as a Class II director of the Board.
On April 22, 2024, Clover Health Investments, Corp. (the “Company”) announced that Peter Kuipers will become Chief Financial Officer of the Company, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the day after the filing of the Company’s Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024, as approved by the Board of Directors of the Company on April 16, 2024.
Mr. Kuipers will succeed Terrence Ronan, the Company’s current Interim Chief Financial Officer, who will continue in his role as Interim Chief Financial Officer until Mr. Kuipers becomes Chief Financial Officer, and thereafter cease to serve as the Company’s principal financial officer and principal accounting officer.
Max materiality 0.90 · Median 0.65 · Most common event earnings